Technical Analysis for LYEL - Lyell Immunopharma, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.98 | -5.12% | -0.05 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | -5.13% | |
| Hammer Candlestick | Bullish | -5.13% | |
| Volume Surge | Other | -5.13% | |
| Wide Bands | Range Expansion | -5.13% | |
| 20 DMA Resistance | Bearish | -11.96% | |
| MACD Bearish Signal Line Cross | Bearish | -11.96% | |
| Narrow Range Bar | Range Contraction | -11.96% | |
| Wide Bands | Range Expansion | -11.96% | |
| 20 DMA Resistance | Bearish | -11.96% | |
| Wide Bands | Range Expansion | -11.96% |
| Alert | Time |
|---|---|
| Down 5% | about 3 hours ago |
| Down 3% | about 3 hours ago |
| 60 Minute Opening Range Breakdown | about 3 hours ago |
| Down 2 % | about 4 hours ago |
| Down 1% | about 4 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/07/2024
Lyell Immunopharma, Inc. Description
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers, as well as ovarian and other solid tumors; LYL845, an IV administered autologous TIL therapy for multiple solid tumors; and NY-ESO-1, a T cell product candidate for synovial sarcoma and other solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California with additional offices in Seattle and Bothell, Washington.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Life Sciences Biology Solid Tumors Stem Cell Cell Biology Non Small Cell Lung Cancer Induced Stem Cells Cloning Treatment Of Non Small Cell Lung Cancer Synovial Sarcoma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.2556 |
| 52 Week Low | 0.85 |
| Average Volume | 1,333,236 |
| 200-Day Moving Average | 1.83 |
| 50-Day Moving Average | 1.20 |
| 20-Day Moving Average | 1.11 |
| 10-Day Moving Average | 1.14 |
| Average True Range | 0.13 |
| RSI (14) | 42.53 |
| ADX | 15.34 |
| +DI | 17.36 |
| -DI | 28.31 |
| Chandelier Exit (Long, 3 ATRs) | 1.11 |
| Chandelier Exit (Short, 3 ATRs) | 1.24 |
| Upper Bollinger Bands | 1.39 |
| Lower Bollinger Band | 0.83 |
| Percent B (%b) | 0.36 |
| BandWidth | 50.95 |
| MACD Line | -0.02 |
| MACD Signal Line | -0.02 |
| MACD Histogram | -0.0065 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.40 | ||||
| Resistance 3 (R3) | 1.38 | 1.25 | 1.34 | ||
| Resistance 2 (R2) | 1.25 | 1.15 | 1.25 | 1.32 | |
| Resistance 1 (R1) | 1.14 | 1.10 | 1.07 | 1.15 | 1.30 |
| Pivot Point | 1.00 | 1.00 | 0.97 | 1.01 | 1.00 |
| Support 1 (S1) | 0.89 | 0.91 | 0.82 | 0.91 | 0.76 |
| Support 2 (S2) | 0.76 | 0.85 | 0.76 | 0.74 | |
| Support 3 (S3) | 0.65 | 0.76 | 0.72 | ||
| Support 4 (S4) | 0.66 |
